Early human studies suggest improved glucose metabolism in key brain regions and potential slowing of cognitive decline in at-risk individuals
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial
Obes Surg 34(4):13241332 Lautenbach A, Wernecke M, Stoll FD, Meyhfer SM, Meyhfer S, Aberel J
Popular GLP-1 weight-loss drugs linked to lower risks of addiction and overdose Popular weight-loss drugs may also help silence the cravings behind addiction, reducing risks across alcohol, nicotine, opioids, and other substances
The most advanced program, Daewoong Therapeutics' CLOPAM platform, achieved over 80% relative bioavailability for semaglutide versus subcutaneous injection in a 70-person Phase 1 study (August 2025)
Even a 15-minute daily walk makes a measurable difference in overall GLP-1 outcomes beyond just constipation relief